Project Grant R01CA315771
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $387K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a Project Grant of $1,847,485 under the Cancer Treatment Research program (CFDA 93.395) to advance next-generation CAR-NK (chimeric antigen receptor-engineered natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025, with completion targeted for August 31, 2029, funds a clinical trial developing IC9/CAR5-28Z/IL-15...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize clonal evolution and immune dysregulation in acute myeloid leukemia patients treated with venetoclax and azacitidine following allogeneic stem cell transplantation. The research addresses post-transplant AML relapse mechanisms by pursuing two primary aims: characterizing the mutational landscape at diagnosis,...
- This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $172,889 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and optimize chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research applies structure-guided protein evolution to improve natural ligand-based CAR-T therapies targeting CD70 in AML. The project uses computational deep learning algorithms and high-throughput...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...